Drug Patents owned by Sandoz Inc
1. List of Angiomax drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7598343 | SANDOZ INC | Pharmaceutical formulations of bivalirudin and processes of making the same |
Jul, 2028
(5 years from now) | |
| US7582727 | SANDOZ INC | Pharmaceutical formulations of bivalirudin and processes of making the same |
Jul, 2028
(5 years from now) | |
|
US7582727 (Pediatric) | SANDOZ INC | Pharmaceutical formulations of bivalirudin and processes of making the same |
Jan, 2029
(5 years from now) | |
|
US7598343 (Pediatric) | SANDOZ INC | Pharmaceutical formulations of bivalirudin and processes of making the same |
Jan, 2029
(5 years from now) | |
Do you want to check out ANGIOMAX patents from before 2022?
Drugs and Companies using BIVALIRUDIN ingredient
Market Authorisation Date: 15 December, 2000
Treatment: NA
Dosage: INJECTABLE;INTRAVENOUS
How can I launch a generic of ANGIOMAX before it's patent expiration?
More Information on Dosage
2. List of Qoliana drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7265117 | SANDOZ INC | Topical brimonidine tartrate formulations that lack chlorine dioxide |
Aug, 2025
(2 years from now) | |
Do you want to check out QOLIANA patents from before 2022?
Drugs and Companies using BRIMONIDINE TARTRATE ingredient
Market Authorisation Date: 22 May, 2006
Treatment: NA
Dosage: SOLUTION/DROPS;OPHTHALMIC
More Information on Dosage
QOLIANA family patents
2
United States
1
Canada
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic